表紙
市場調査レポート

急性リンパ性白血病治療薬の世界市場:2015年〜2019年

Global Acute Lymphocytic Leukemia Therapeutics Market 2015-2019

発行 TechNavio (Infiniti Research Ltd.) 商品コード 345156
出版日 ページ情報 英文 65 Pages
即納可能
価格
本日の銀行送金レート: 1USD=105.42円で換算しております。
Back to Top
急性リンパ性白血病治療薬の世界市場:2015年〜2019年 Global Acute Lymphocytic Leukemia Therapeutics Market 2015-2019
出版日: 2015年11月11日 ページ情報: 英文 65 Pages
概要

世界における急性リンパ性白血病治療薬の市場は、2014年から2019年の間、4.52%のCAGRで拡大することが予測されています。

当レポートは、世界における急性リンパ性白血病治療薬市場の現状と今後の見通しを地域別に提供しており、同疾患の概要、市場の成長因子と課題、主要ベンダーの分析などとともにお届けします。

第1章 エグゼクティブサマリー

  • 概況

第2章 当レポートの調査範囲

  • 市場概要
  • 主要ベンダーの製品

第3章 製品プロファイル

第4章 市場調査手法

  • 調査手法
  • 経済指標

第5章 イントロダクション

  • 主な市場洞察

第6章 市場情勢

  • 市場概要
  • 市場規模と予測
  • ファイブフォース分析

第7章 疾患の概要

  • 病因とリスク因子
  • 病態生理学
  • 症状
  • 疫学
  • 分類
  • 診断
  • 治療と管理

第8章 薬剤投与経路別の市場分類

  • 経口
  • 非経口

第9章 分子タイプ別の市場分類

  • 生物製剤
  • 小分子

第10章 地理区分

  • 世界の急性リンパ性白血病治療薬市場:地域別
  • 南北アメリカ
  • 欧州・中東・アフリカ地域
  • アジア太平洋地域

第11章 市場成長因子

第12章 市場成長因子の影響

第13章 市場の課題

第14章 成長因子と課題の影響

第15章 市場動向

第16章 ベンダー情勢

  • 競合シナリオ
  • 市場シェア分析
  • その他の有力ベンダー

第17章 主要ベンダーの分析

  • Amgen
  • Bristol-Myers Squibb
  • Novartis

第18章 付録

  • 略語リスト

第19章 Technavioについて

目次
Product Code: IRTNTR7891

Covering: An in-depth study of the acute lymphocytic leukemia market and segmentation by route of administration (oral and parenteral), by type of molecules (biologics and small molecules), and by geography (the Americas, EMEA, and APAC). The report also presents a detailed analysis of the top companies operating in the market, including Amgen, Bristol-Myers Squibb, and Novartis.

Market landscape of acute lymphocytic leukemia

Acute lymphocytic leukemia or acute lymphoblastic leukemia, is a malignancy of the blood cells that affects the lymphoblasts or leukemic blasts, which witnesses an uncontrolled cell division. The main symptoms a patient exhibits are weakness, tiredness, dizziness, fever, shortness of breath, frequent infections, bruising, and bleeding.

Currently, the disease cannot be cured completely but the risk can be reduced by administering medication.

Technavio's market research analysts expect the global acute lymphocytic leukemia market to grow at a steady rate and post a CAGR of over 4% during the forecast period. One of the major factors contributing to the growth of the market is the provision for orphan drugs. For instance, in the US, orphan designation for a drug means incentives like tax credits for qualified clinical testing, exemption from prescription drug user fees unless indicated for additional non-orphan indications, and market exclusivity for seven years.

Segmentation of the acute lymphocytic leukemia market by route of administration

  • Oral
  • Parenteral

Many medications are administered through the oral route to guarantee a systemic effect. The oral route is a sub-division of enteral administration and is considered to be one of the safest and most preferred routes of drug administration.

Geographical segmentation of the acute lymphocytic leukemia market

  • Americas
  • APAC
  • EMEA

With a share of over 49%, the Americas dominated the acute lymphocytic leukemia market, with the US being the major revenue contributor. The Americas is closely followed by the EMEA and the APAC region and the market is expected to follow a similar trend during the forecast period.

Competitive landscape and key vendors

The acute lymphocytic leukemia market is marked by the presence of both global and local drug manufacturers with varied product portfolios containing generic and off- label drugs as well as branded therapies. Besides, the high level of unmet medical need is expected to give a platform to the vendors to develop products to cater to relevant areas and enhance their market shares.

Primary vendors in this market are -

  • Amgen
  • Bristol-Myers Squibb
  • Novartis

Other prominent vendors included in this report are Ariad, Arno Therapeutics, Baxter, Boehringer Ingelheim, ERYTECH Pharma, Fate Therapeutics, Jazz Pharmaceuticals, Orphan Europe, Otsuka, Ono Pharmaceuticals, Onconova Therapeutics, Pfizer, Regeneron Pharmaceuticals, Sanofi, and Sigma-Tau Pharmaceuticals.

Key questions answered in the report include

  • What will the market size and the growth rate be in 2019?
  • What are the key factors driving the global acute lymphocytic leukemia market?
  • What are the key market trends impacting the growth of the global acute lymphocytic leukemia market?
  • What are the challenges to market growth?
  • Who are the key vendors in the global acute lymphocytic leukemia market?
  • What are the market opportunities and threats faced by the vendors in the global acute lymphocytic leukemia market?
  • What are the trending factors influencing the market shares of the Americas, EMEA, and APAC?
  • What are the key outcomes of the five forces analysis of the global acute lymphocytic leukemia market?

Technavio also offers customization on reports based on specific client requirement.

Table of Contents

PART 01: Executive summary

  • Highlights

PART 02: Scope of the report

  • Market overview
  • Top-vendor offerings

PART 03: Product profiles

PART 04: Market research methodology

  • Research methodology
  • Economic indicators

PART 05: Introduction

  • Key market highlights

PART 06: Market landscape

  • Market overview
  • Market size and forecast
  • Five forces analysis

PART 07: Disease overview

  • Etiology and risk factors
  • Pathophysiology
  • Symptoms
  • Epidemiology
  • Classification
  • Diagnosis
  • Treatment and management

PART 08: Market segmentation by route of administration

  • Oral
  • Parenteral

PART 09: Market segmentation by type of molecules

  • Biologics
  • Small molecules

PART 10: Geographical segmentation

  • Global acute lymphocytic leukemia therapeutics market by geography 2014
  • Acute lymphocytic leukemia market in Americas
  • Acute lymphocytic leukemia market in EMEA
  • Acute lymphocytic leukemia market in APAC

PART 11: Market drivers

PART 12: Impact of drivers

PART 13: Market challenges

PART 14: Impact of drivers and challenges

PART 15: Market trends

PART 16: Vendor landscape

  • Competitive scenario
  • Market share analysis
  • Other prominent vendors

PART 17: Key vendor analysis

  • Amgen
  • Bristol-Myers Squibb
  • Novartis

PART 18: Appendix

  • List of abbreviation

PART 19: Explore Technavio

List of Exhibits

  • Exhibit 01: Product offerings
  • Exhibit 02: Global acute lymphocytic leukemia therapeutics market 2014-2019 ($ millions)
  • Exhibit 03: Five forces analysis
  • Exhibit 04: Global acute lymphocytic leukemia therapeutics market by geography 2014
  • Exhibit 05: Global acute lymphocytic leukemia therapeutics market revenue by geography 2014-2019 ($ millions)
  • Exhibit 06: Global acute lymphocytic leukemia therapeutics market revenue by geography (percentage)
  • Exhibit 07: Acute lymphocytic leukemia market in Americas 2014-2019 ($ millions)
  • Exhibit 08: Acute lymphocytic leukemia market in EMEA 2014-2019 ($ millions)
  • Exhibit 09: Acute lymphocytic leukemia market in APAC 2014-2019 ($ millions)
  • Exhibit 10: Impact of drivers
  • Exhibit 11: Impact of drivers and challenges
  • Exhibit 12: Key takeaways: Amgen
  • Exhibit 13: Global sales of Sprycel 2012-2014 ($ millions)
  • Exhibit 14: Key takeaways: Bristol-Myers Squibb
  • Exhibit 15: Global sales of Gleevec/Glivec 2012-2014 ($ millions)
  • Exhibit 16: Key takeaways: Novartis
  • Exhibit 17: Amgen: Business segmentation by revenue 2014
  • Exhibit 18: Amgen: Business segmentation by revenue 2013 and 2014 ($ billions)
  • Exhibit 19: Amgen: Geographical segmentation by revenue 2014
  • Exhibit 20: Business segmentation by revenue 2013 and 2014 ($ billions)
Back to Top